Novartis announces trial setback on del-desiran drug

Novartis said its late-stage del-desiran trial in myotonic dystrophy failed to meet a key efficacy endpoint, creating a setback for the muscle-wasting disease candidate. The company nonetheless reaffirmed its sales guidance through 2030, limiting the negative read-through to its broader growth outlook.